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Background: Children receiving Total Body Irradiation (TBI) in preparation for
Hematopoietic Stem Cell Transplantation (HSCT) are at risk for Growth Hormone
Deficiency (GHD), which sometimes severely compromises their Final Height (FH). To
better represent the impact of such therapies on growth we apply a mathematical
model, which accounts both for the gompertzian-like growth trend and the
hormone-related ‘spurts’, and evaluate how the parameter values estimated on the
children undergoing TBI differ from those of the matched normal population.
Methods: 25 patients long-term childhood lymphoblastic and myeloid acute
leukaemia survivors followed at Pediatric Onco-Hematology, Stem Cell Transplantation
and Cellular Therapy Division, Regina Margherita Children’s Hospital (Turin, Italy) were
retrospectively analysed for assessing the influence of TBI on their longitudinal growth
and for validating a new method to estimate the GH therapy effects. Six were treated
with GH therapy after a GHD diagnosis.
Results: We show that when TBI was performed before puberty overall growth
and pubertal duration were significantly impaired, but such growth limitations were
completely reverted in the small sample (6 over 25) of children who underwent GH
replacement therapies.
Conclusion: Since in principle the model could account for any additional growth
‘spurt’ induced by therapy, it may become a useful ‘simulation’ tool for paediatricians for
comparing the predicted therapy effectiveness depending on its timing and dosage.
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Growth is a finely regulated phenomenon that results from interaction of genetics,
nutrition, hormones, metabolism and cerebrocortical influences: in childhood it is
largely influenced by growth hormone (GH) and in puberty by the synergistic action
of GH and sex steroids. Puberty is the period of human development during which
physical growth completes and sexual maturation occurs; this condition implies
becoming first capable of sexual reproduction and is marked by the maturation of
the genital organs and the development of the sexual secondary characteristics. The
normal pubertal growth rate (complete enlargement degree) is approximately 1.5–2
times greater than the prepubertal growth rate. GH stimulates growth of epiphyseal
cartilage and subsequent bone growth directly by action of Insulin-like growth factor© 2014 Galletto et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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delayed and the divergence of the growth rate from normal increases with age unless
replacement therapy is administered [1].
High-dose chemotherapy or chemo-radiotherapy followed by hematopoietic stem
cell transplantation (HSCT) used to treat children with cancer has resulted in an
ever-increasing number of long-term survivors. These patients are at risk for a variety
of late effects due to the disease itself, treatment exposure (surgery, chemotherapy
and radiotherapy) and possible underlying medical problems. Patients who received
total body irradiation (TBI) in preparation for HSCT are at risk of developing a deficiency
of one or more hormones produced by the hypothalamus and pituitary gland (HP region):
both these treatments are known to affect growth and development. Chemotherapy,
decreased nutritional intake, hematopoietic stem cell transplantation, corticosteroids and
other endocrinological complications (hypothyroidism and hypogonadism) may also affect
growth in childhood cancer survivors, but to a lower extent [2-4].
The incidence of GH deficiency (GHD) after TBI and HSCT varies from 20 to 85%
depending upon differences in time of testing after HSCT, differences in preparative
regimen received, inclusion of patients with and without cranial irradiation and use of
different methods of GH testing, as described in a recent review [1].
It has been suggested that risk factors like higher CRT (cranial radiotherapy) dose,
larger fraction size or larger number of fractions, increased volume of the HP region
exposed, higher biological effective dose (BED), younger age at treatment and longer
follow up time affect the risk of GHD secondary to radiation of the HP region [5,6]. In
addition, gender (male sex) may also influence the prevalence of GHD. GH therapy is
able to gain a total height inversely related to patient age at the start of GH treatment
and positively related to its duration. Treatment with GH before the child’s height has
decreased to below the third percentile results in the greatest final height response to
treatment. Growth before puberty is the major determinant of final height, therefore
treatment with GH during the prepubertal period needs to be optimized.
Traditionally juvenile growth is evaluated by comparison with appropriate Height
Growth Charts (HGC), which report proper statistical parameters (usually the 25th,
50th and 75th centiles of the heights extracted from measurements performed in large
homogeneous populations) versus age (see for instance [7-9]). In order to model the
growth from early childhood to maturity, alternative approaches have been proposed
[10]. Gliozzi A et al. [11] have recently presented an alternative method for the fitting
and modelling of human HGC and individual (longitudinal) growth curves, based on
the formalism of the Phenomenological Universalities (PUN) [12], already used in the
analysis of several datasets of great relevance for growth and to verify the influence of
the different parameters.
We evaluated if such a model can be useful to assess the influence of TBI on longitu-
dinal growth. In fact, given the differences between individual timing and sequence of
the pubertal events, as well as the individual response to therapies, to compare the
genuine patient growth data with proper ‘growth chart’ references can be misleading.
On the contrary, the model uses the data of the patients for fitting the values of a few
meaningful model parameters. Some of those parameters are related to the prepubertal
growth, which in most cases are not influenced by TBI and other HSCT conditioning
therapies, but simply reflect the individual ‘growth potential’. Other parameters strictly
Galletto et al. Theoretical Biology and Medical Modelling 2014, 11:44 Page 3 of 11
http://www.tbiomed.com/content/11/1/44describe pubertal growth, and are expected to be highly sensitive to TBI. Such values
will be finally compared with those pertaining to the reference growth curve, aiming at
assessing the quantitative impact of TBI on growth. The goal of the present paper is to
validate this alternative method in a setting of long term leukemia survivors who
underwent to HSCT and to assess if it would be able to estimate the GH therapy effects
and to suggest a predictive algorithm to personalize GH therapy and to simulate its
effect on the final height (FH).
Methods
Patients and intervention
Patients described in this monocentric retrospective study were all included in a long-term
oncological and endocrinological follow-up or childhood lymphoblastic and myeloid acute
leukaemia survivors performed at Pediatric Onco-Hematology, Stem Cell Transplantation
and Cellular Therapy Division, Regina Margherita Children’s Hospital, Turin, Italy; these
children were diagnosed at Our Centre between 15/05/1988 and 29/06/2005. Although,
according to the Italian regulations, for retrospective studies that did not involve additional
withdrawals but only the extrapolation of data from existing medical records and where
retrospective data is anonymous authorizations are not strictly due, we required and
obtained the Ethic Committee approval (see Additional file 1).
Patients were eligible for this study if they met all the following inclusion criteria: (1)
having undergone HSCT for childhood acute leukaemia after a myeloablative condi-
tioning regimen, (2) having an italian origin, (3) having undergone an oncological and
endocrinological at least 5-year long follow-up after HSCT with a complete growth
evaluation (4) having at least one height measurement before TBI and a follow up
lasting until sexual maturation. Patients who developed a second malignant tumor or
who achieved final height in a short follow up period were excluded. Hormone therapy
was never administered to promote puberty.
Out of 90 patients diagnosed and treated at our hospital between 1988 and 2005, twenty-
seven young long term survivors met these inclusion criteria and are described here. All
patients has been followed by oncologists and endocrinologists possibly until the age of 18
and they all were in remission without complications at the time of this study. All the
patients have been treated at our hospital according to the AIEOP (Associazione Italiana
Ematologia-Oncologia Pediatrica-Italian Association of Pediatric Onco-Hematology)-BFM
(Berlin–Frankfurt–Munster) ALL and AML Protocols, and had received TBI as part of their
conditioning regimen before HSCT. Patients features are summarized in Table 1. Further
details about patients who underwent GHTare given as Additional file 1.
Two female patients, one not (n. 19) and one (n. 26) undergoing GHT, were excluded
by the samples because the estimated values were not reliable. In the first case the
number of available data was too small to get a reasonable fitting of the parameters,
in the second case we realized that GHT, delivered between 8 and 9 years of age, was
very effective and the corresponding growth spurt was misinterpreted by the numerical
program as the age of puberty.
Preparative regimens to HSCT
The preparative regimen depended on the protocols in use at the time of transplant-
ation, the underlying disease and its status, and the existence or not of previous
Table 1 Detailed list of the patients considered in the present study
Patient Sex Age at TBI (years) GH therapy (Y/N)
1 F 8.4 N
2 F 1.1 N
3 M 10.4 N
4 M 5.0 N
5 M 6.3 N
6 F 6.9 N
7 F 7.0 N
8 M 7.3 N
9 F 13.5 N
10 M 10.6 N
11 M 6.9 Y
12 F 11.2 N
13 F 4.9 Y
14 M 14.2 N
15 F 12.7 N
16 F 6.8 Y
17 F 6.3 Y
18 M 8.0 N
20 M 4.9 Y
21 M 5.3 N
22 F 2.8 N
23 M 12.2 N
24 F 7.3 N
25 M 13.0 N
27 F 9.3 Y
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and all patients received the same total dose of 12 Gy (that is, 2Gy twice daily during
3 days). TBI was associated to etoposide, to etoposide and cyclophosphamide, to
melphalan (5 patients respectively), to thiotepa and cyclophosphamide (5 patients), to
cyclophosphamide and to fludarabine (1 patient in both cases), to fludarabine and
thiotepa (2 patients).Growth evaluation
Height was measured at first diagnosis, at the beginning of the second line therapy in
case of leukemia relapse, at starting of preparative regimen to HSCT and then every
six/twelve months until 18 years of age, as part of endocrinological examinations
follow up. From these measurements it was possible to obtain information on the
pubertal growth in terms of overall growth (complete enlargement) and growth
velocity (heightening speed; cm/year). Standing height, measured using a Harpenden
stadiometer, was used for all patients. Final height (FH) was defined as the tallest
height measured when the patient’s age was 18 years or older, and when height velocity
was less then 1 cm per year.
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The diagnosis of GHD in childhood is a multifaceted process requiring comprehensive
clinical and endocrinological assessment, combined with biochemical tests of the
GH-insulin-like-growth factor (IGF) axis. Criteria to initiate investigation include: 1)
severe short stature, defined as a height more than 3SD below the mean; 2) height
more than 1.5 SD below the midparental height; 3) height more than 2SD below the
mean and a height velocity over 1 yr more than 1 SD below the mean for chronological
age, or a decrease in height SD more than 0.5 over 1 yr in children over 2 yr of age; 4) in
the absence of short stature, a height velocity more than 2 SD below the mean over 1 yr
or more than 1.5 SD sustained over 2 yr.
Growth hormone (GH) deficiency was detected by measuring insulin-like growth factor
I plasma levels and GH peak response to at least two stimulation tests per patient (first
test: Arginine, second test glucagon or insulin). GH insufficiency was diagnosed when
peak GH levels after stimulation were inferior to 10 mcg/L [13].
For patients who underwent a GH therapy we considered: length at birth, target
height; somatomedins and other biochemical abnormalities at the start of therapy; age
at beginning of GH therapy dose and duration. Nobody had thyroid disfunction; only
one patient had gonadal disfunction (patient 6) (see Additional file 1).Physical model
Growth is described, according to [11] and the parameters listed in Table 2, using an
algorithm which assumes that, starting from an initial height y0, (actually corresponding
to 3-months stature) a gompertzian [14] lengthening with growth rate a0 and carrying
capacity related parameter k0 occurs.
Following endogenous hormones production, growth shows accelerations or ‘spurts’ at
mid-childhood and at adolescence. The last, concomitant with puberty, is the predominant
one and can be modeled as a Gaussian-like velocity spurt with growth rate a1 occurring at
the average age of tm, and with a time distribution given by a variance σ, which causes an
overgrowth y1.
The above model can be expressed by the Eq:
y ¼ y0exp
k0
a0
1−exp −a0 tð Þð Þ
 
þ y1exp
k0
a1
1−exp −a1 t−tmð Þð Þð ÞG tm; σð Þ
 
ð1Þ
being G the Gauss cumulative function:
G tm; σð Þ ¼ 1ffiffiffiffiffiffi
2π
p
Z∞
−∞
e
t−tmð Þ2
2σm2 dt ð2Þ
The above equations can be used for fitting individual growth data (longitudinal studies)as well as HGC (transversal studies) [7-9]. A dedicated MATLAB® program fitted the
parameter values which best interpolate the growth curve of the model with the avail-
able data describing the height of each patient. A more exhaustive explanation of the
mathematical procedure can be found in Gliozzi et al. [11].
Table 2 Detailed list of parameter values evaluated by the model
Case Y0
(height at
3 months
in cm)
k0
(carrying
capacity)
a0 (pre-
pubertal
growth
rate)
tm
(age at
puberty)
y1
(overgrowth
due to puberty
in cm)
a1
(pubertal
growth
rate)
σ (puberty
time span
in yrs)
1 62.39727 0.190254 0.218913 11.84713 12.22394 4.497026 0.591718
Females 2 56.18536 0.26937 0.276819 10.50654 8.135071 1.232418 1.748695
6 58.33898 0.248981 0.294922 11.18104 11.66339 1.030791 1.519584
7 63.2854 0.1975 0.2324 9.655209 7.9907 7.2763 0.3051
9 62.229 0.192012 0.217 10.25788 9.588047 1.399609 1.212012
12 62.33923 0.192248 0.224598 13.43577 6.946294 6.07616 1.31218
15 63.92922 0.172435 0.198459 10.84313 5.841731 9.715973 0.577892
22 62.3936 0.1903 0.2189 10.85878 12.2237 4.4767 0.5918
24 53.83767 0.257778 0.274054 12.86398 9.008473 7.301078 1.27438
13 70.89 0.097948 0.110792 10.16677 5.630503 4.339571 0.667967
16 73.39873 0.08876 0.119807 12.92137 18.89658 5.471942 0.17205
17 61.28031 0.19219 0.271627 11.60383 28.09531 0.869462 4.42738
27 60.32773 0.201376 0.217701 11.45546 2.54826 1.79574 0.001265
Reference
values 50th
centile HGC
61.94 0.187 0.218 10.31 15.24 0.61 2.01
3 72.35844 0.101311 0.135207 13.7949 7.091698 1.333014 0.670117
Males 4 68.32549 0.146165 0.189528 20.01918 3.759593 4.040935 3.719143
5 66.97872 0.146127 0.161664 12.5558 6.622826 2.100794 0.592351
8 71.88692 0.10269 0.122161 12.89852 8.895164 4.251733 1.715174
10 65.03691 0.164741 0.169928 11.92245 6.199538 9.831924 0.705535
14 61.74667 0.212759 0.244471 11.54411 15.17584 0.679802 2.016547
18 67.1999 0.129419 0.14843 13.2384 11.72742 2.069234 0.817563
21 78.24132 0.065035 0.090613 14.88816 17.0507 1.35473 0.851504
23 69.22207 0.137272 0.154906 15.0422 6.979829 2.339744 0.525147
25 69.0407 0.138559 0.148518 12.96021 13.12342 −0.18501 1.492829
11 66.39639 0.148124 0.204369 12.50947 11.13404 1.148798 1.087921
20 75.0882 0.099678 0.123619 11.29312 6.9798 2.3397 0.5251
Reference
values 50th
centile HGC
67.82 0.136 0.149 12.79 14.73 0.84 1.45
Patients reported in bold underwent TBI+GH therapy.
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The difference Δ between the values estimated by the model for each patient given in
Table 2 and the 50th centile of appropriate HGC has been computed for each variable.
The sample size is given in brackets. The mean and the related 95% Confidence Interval
(95% C.I.) of Δ were calculated for all the patient of the study (N = 25), for those undergo-
ing TBI but not GH therapy (N = 19) and for male (N = 10) and female (N = 9) separately.
Similar statistics were calculated for the group of children who received both TBI and GH
therapy (N = 6). In this analysis gender was not considered for the limited sample size
available. Whenever the range of Δ corresponding to the 95% C.I. did not overlap the
vertical line of null values, the result was considered significantly (p = 0.05) different from
the null hypothesis. The central point of the Δ range is the mean value of the difference
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being it negative (positive) means that the parameter is smaller (larger) of the given
extent than expected.Results
Figure 1 (a and b) reports the height of the 12 males and 13 females included in the
present study, comparing their stature with their reference, i.e. the 50-th centile of
appropriate HGC. The 25-th centile is reported as well. It shows that growth is severely
impaired and the Final Height is always lower than the reference values except for one
case (male n.25).
As shown in Figure 2, assuming as reference the 50th centiles of appropriate HGC,
we considered the patients undergoing TBI without a following GH therapy (n = 19) (b)
10 males and 9 females undergoing TBI (c) and we compared them to their reference.
The statistical analysis showed that the 19 patients undergoing TBI exhibited a normal
pre-pubertal growth but significantly differ from their reference in the overall pubertal
growth (-5.5 cm), in the pubertal growth velocity (+3.0 cm/yr) and in the average
(+1.0 yr) and standard deviation of the time of pubertal growth (-0.5 yr). Moreover,
when the genders were separately considered, all the above parameters were still signifi-
cantly different from normal for females, while the males who underwent TBI only
show a reduced pubertal growth in comparison with their reference.
Comparing patients undergoing TBI before (n = 14) (Figure 3a) and after the average
time of puberty (n = 5) (Figure 3b) versus the respective reference, we observed that
patients undergoing TBI before puberty (n = 14) showed a delayed mean pubertal age
(+1.34 yr), a reduced pubertal growth (-5.9 cm), an increased post-pubertal growthFigure 1 Reports the height of the 12 males and 13 females considered in the present study,
comparing their stature with the 50-th and 25-th centile of appropriate HGC. Patients are divided
between those who have not (on the left) and those who have (on the right) undergone Growth
Hormone Therapy (GHT).
Figure 2 Plot of the 95% Confidence Interval of the variable Δ = value estimated by the model on
the sample - value estimated by the model on the 50th centile of appropriate HGC for all the model
parameters. The considered samples are the total of the patients undergoing TBI but not GH therapy
(a), the subsample formed by the males (b) and by the females (c).
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(-0.6 yr). Those undergoing TBI later than puberty showed a normal growth.
Six patients (4 females and 2 males) received GH therapy after TBI and HSCT. As
described in Figure 4, if we add to the previous sample (N = 19) also these patients, the
same parameters which significantly differed from normal population still did so. DueFigure 3 Plot of the 95% Confidence Interval of the variable Δ = value estimated by the model on
the sample - value estimated by the model on the 50th centile of appropriate HGC for all the model
parameters. The considered samples are the patients undergoing TBI before (a) and after (b) the average
time of puberty.
Figure 4 Plot of the 95% Confidence Interval of the variable Δ = value estimated by the model on
the sample - value estimated by the model on the 50th centile of appropriate HGC for all the model
parameters. The considered samples are the patients undergoing only TBI or TBI + GH therapy (a) and
those undergoing TBI + GH therapy (b).
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evaluated for this sample has a low ‘weight’ in comparison with those pertaining to the
other 19 patients who didn’t undergo any GH replacement therapy.
Finally, comparing growth after TBI (N = 19) with TBI + GH therapy (N = 6), the statis-
tical analysis showed that no one of the above considered parameter significantly differed
anymore from those pertaining to the normal population. GH therapy proved therefore
effective in reversing the effect of TBI on pubertal growth. Such a ‘catch up’ effect is quite
interesting and, although few (N = 6) cases have been studied up to now, gives a very
positive feedback about the effectiveness of the GH replacement therapy administered
in our clinical context.Discussion and conclusions
Intensive chemotherapy regimens with or without CNS irradiation are associated with
persistent growth impairment [1,2,15-17], a multifactorial process implicating first-line
treatments, post transplant complications and their consecutive treatments, prolonged
use of steroid for GVHD and myeloablative conditioning regimens [18-22] either following
TBI or cranial radiotherapy, which has similar effects on the hypothalamus and pituitary
gland. Conditioning regimens seem to alter growth throughout the combined effects of
lesions of the hypothalamic-pituitary gland axis, multiple endocrine dysfunction (thyroid
and gonadal) and damage to the bone epiphyses [1,23-27].
In our study 25 long-term leukemia survivors were retrospectively analyzed for asses-
sing the influence of TBI on their longitudinal growth and for validating a new method to
estimate the GH therapy effects. Six were treated with GH therapy after a GHD diagnosis.
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and compared with the values corresponding to the 50th centile of the appropriate
HGC. All the values of the parameters referring to the prepubertal status (y0, a0, k0)
were never significantly different from those of the normal population, confirming that
TBI and all the related therapies were delivered to a sample extracted by the general
population. On the contrary, TBI impacted on the post-puberal parameters both for
males and females and also GH therapy following TBI and HSCT proved effective in
compensating TBI-induced growth limitation. Our analysis confirms that TBI severely
affects the post-pubertal growth parameters, mainly the overall growth and the pubertal
duration, expecially when it was performed before puberty [28]. Although only a very
small sample was available, we also showed that the above growth limitations are
significantly reduced when GH therapy follows TBI. Furthermore, a possible bias of the
program has to be assessed, since the program interprets any growth discontinuity,
maybe due to effective GHT, as puberty. A careful check of the data should always been
performed before processing.
In conclusion, the value of the post-pubertal parameters have been shown to be
changed by GH therapy but, due to the small number of patients included in the
present study, we were unable to relate those value to very important factors, such as
the specific drug and dosage, the age at which the therapy was started, its duration, etc.
At the moment we can just speculate that such mathematical approach can open a
new working prospective towards ‘personalized treatments’. A larger, possible multi-
centric, study could in principle discriminate all the above factors and evaluate their
specific different impact on the model parameters. At that time, being the model able
to produce longitudinal curves on the basis of the values of those parameters, it could
be used as a sort of “clinical simulator” in order to predict the final effect of any spe-
cific dose of GH and, even more remarkably, of the timing of the therapeutic treatment,
helping pediatricians and endocrinologists to find the best clinical protocol for follow
up and treatment also in long term cancer survivors.
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